Tobias Aloha

Scientist

[Tobias Aloha @TobiasAloha]

@bigal_com @BabakGhorb18348 Thank you Mr Big Al for your feed back. I totally agree. HR better than 0.7 will be fantastic for this hard to treat disease.

[Tobias Aloha @TobiasAloha]

$GRTS. Only logical conclusion to draw from current delay of data release is GRTS working to secure a deal. mPFS should be reasonable, although doubt statistical significance. GRTS own IPs with competitive edge over competitors. In worst case scenario, GRTS will secure a BO.

[Tobias Aloha @TobiasAloha]

Developing a Neoantigen-Directed Cancer Vaccine with Gritstone Bio https://t.co/qkqbLTxIts

$GRTS
GRTS
For those who missed the webinar

[Tobias Aloha @TobiasAloha]

@bigal_com @ThePhillyZoo As we speak, I’m certain that there is a bidding war happening behind the scene. Whoever wins own the forefront of the next vaccine race.

[Tobias Aloha @TobiasAloha]

@bigal_com @ThePhillyZoo It’s ok Mr Big Al. If $GRTS failed, we are all going to blame you for the misleading tips. LOL JK. But seriously, LFG!!

[Tobias Aloha @TobiasAloha]

@scottm2032 My prediction is that there will be a separation of PFS curves but not statistically significant yet due to the short interim analysis. Ideally the interim analysis happened in Q4 instead. My guess is announcement of ID deal before release of GRANITE data to bump share price.

[Tobias Aloha @TobiasAloha]

With time and money running out for $GRTS, there will be a deal coming. Not further dilution. Arcturus got $4.3 billion deal from CSL for samRNA vaccine. $GRTS can certainly do the same with CORAL validated by BARDA. GRANITE is working but more time and data needed for maturity

[Tobias Aloha @TobiasAloha]

@AAABiotech @BARDA Japan is rolling out samRNA COVID vaccine by Arcturus in November. Time to move forward with 2nd generation vaccine. $GRTS can sell CORAL to big pharma to fund future oncologic projects.

[Tobias Aloha @TobiasAloha]

@bigal_com Looking forward to the deal announcement. Question is which big pharma wants to partner with $GRTS. Any deal is better than no deal at this point. $GRTS took out only $32.5 m in April understanding that the company needs to make a deal at this stage.

[Tobias Aloha @TobiasAloha]

@bigal_com @scottm2032 I’m with you Big Al. I believe this second interim analysis, although may not be of statistical significance due to the short follow up, will show meaningful overall mPFS trend. Regardless, $GRTS is at the negotiation table. Will sell vaccine program and partner granite.

[Tobias Aloha @TobiasAloha]

1L metastatic CRC has mPFS of 10m for overall (combining low and high ctDNA). For the low ctDNA group, mPFS is expected to be > 10m. With the next release of data by $GRTS, we expect to see separation of curves which indicates overall trend, and hopefully strong partnership.

[Tobias Aloha @TobiasAloha]

During KOL by $GRTS, AA stated focusing on overall PFS in the upcoming mature P2/3. Similarly to Moderna’s melanoma RFS data, GRTS low ctDNA group may be starting to show separation of curves but not as dramatically as the high ctDNA groups in this short interval study.

[Tobias Aloha @TobiasAloha]

@Monsoon1494091 Any way I look at it, PFS will be positive based on the past data. Impatience and misunderstanding of the prelim data brought the share price down. $GRTS needs capital moving forward. Selling ID asset will fund future oncologic projects. No way this company is going bankrupt.

[Tobias Aloha @TobiasAloha]

@CryptoProJoe @scottm2032 Glad you mentioned this because clearly there is more to the story. I don’t believe $GRTS intentionally misled investors with BARDA termination, but must have had enough reason to believe that the project was still alive.